A combination of chemotherapy and endocrine therapy offers the promise of long-term recurrence-free survival for patients with hormone receptor (HR)-positive, HER2-negative, node-negative breast cancer, despite having a biologically high risk of disease recurrence. Yesterday’s Late-Breaking…
Read More
Non-chemotherapy-based combination therapies may play a possible role for the treatment of women with HER2-positive (HER2+) tumours, as by selectively targeting a specific group of patients, there is a greater opportunity to achieve control of…
Read More
Offering the trastuzumab–chemotherapy combination to all those with HER2-positive early-stage breast cancer has benefitted many but has led to the overtreatment of an increasing proportion of patients. Adding unnecessary treatments to an effective regimen increases…
Read More
The topic was debated on Saturday in a session as part of the Young Oncologist Track, highlighting the pros and cons of the two different approaches currently in use. There is no question that the clinical benefit and safety…
Read More
